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Abstract
Background: Tuberous Sclerosis Complex (TSC) is an autosomal dominant hamartoma disorder
with variable expression for which treatment options are limited. TSC is caused by a mutation in
either the TSC1  or  TSC2  genes, whose products, hamartin and tuberin, function as negative
regulators in the highly-conserved mammalian target of rapamycin (mTOR) signaling pathway.
Rapamycin (also known as sirolimus), an mTOR inhibitor, has been shown to reduce disease
severity in rodent models of TSC and is currently being evaluated in clinical trials in human
populations. The cytokine interferon-gamma (IFN-γ) is also a potential therapeutic agent for TSC.
A high-expressing IFN-γ allele has been associated with reduced disease severity in human TSC
patients and it has been shown in mouse models that treatment with exogenous IFN-γ reduces
disease severity.
Results: Here, we examine the effects of treating Tsc2+/- mice at different time points with a
rapamycin analog (CCI-779) as a single agent or with a combination of CCI-779 and IFN-γ. We
observed that administering a short course of CCI-779 or CCI-779 plus IFN-γ reduced the severity
of kidney lesions if administered after such lesions develop. As long as treatment is given after
lesions arise, altering the time period during which treatment was given did not significantly impact
the effect of the treatment on disease severity. We did not observe a significant benefit of
combination therapy relative to treatment with a rapamycin analog alone in Tsc2+/- mice. We also
compared timing of treatment and two mTOR inhibitors (rapamycin and CCI-779) in nude mice
bearing Tsc2-/- tumors.
Conclusion: Preventing the genesis of TSC-related kidney lesions in Tsc2+/- mice is not an effective
treatment strategy; rather, the presence of growing tumors appears to be the most important
factor when determining an appropriate treatment schedule. Treatment with rapamycin was more
effective in reducing tumor growth and improving survival in nude mice bearing Tsc2-/- tumors and
also resulted in higher rapamycin levels in blood, brain, and kidney tissue than treatment with an
equal milligram dose of CCI-779. We anticipate these results will influence future preclinical and
clinical trials for TSC.
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Background
Tuberous Sclerosis Complex (TSC) is an autosomal dom-
inant tumor disorder that affects multiple organs, includ-
ing the heart, lungs, brain, skin, and kidneys [1] and
occurs at a frequency of about 1:6000 [2]. It has been esti-
mated that 60–80% of TSC patients develop kidney angi-
omyolipomas (tumors composed of abnormal smooth
muscle cells, fat cells, and blood vessels)[1]. A number of
other medical issues, such as skin lesions (facial angiofi-
bromas, shagreen patches, hypomelanotic macules,
ungual fibromas, and forehead plaques), seizures, cogni-
tive impairment, cortical tubers, cardiac rhabdomyomas,
and in postpubertal females, TSC-related lymphangiolei-
omyomatosis (LAM), are also common in TSC
patients[3].
TSC is caused by a loss of function of one of two genes,
TSC1 or TSC2[2]. The products of these genes, hamartin
and tuberin, function to negatively regulate mTOR in the
highly conserved mTOR signaling pathway [4,5]. When
tuberin and/or hamartin are absent or nonfunctional,
mTOR is constitutively active and its downstream effec-
tors, p70 S6 kinase (S6K), S6 ribosomal subunit (S6) and
eukaryotic initiation factor 4E binding protein 1 (4EBP1)
are hyperphosphorylated, which results in increased cell
growth, cell proliferation, and survival[6,7]. Using com-
pounds designed to inhibit mTOR is a common strategy
in the investigation of possible treatments for TSC.
Rapamycin (Rapamune™ or sirolimus, Wyeth, Madison,
NJ) is an FDA-approved mTOR inhibitor currently used to
prevent rejection of solid organ transplants [8]. Rapamy-
cin and its analogs have been successfully used to treat
TSC-related lesions in rodent models [9-11] and rapamy-
cin is currently being evaluated for its safety and efficacy
in treating TSC-related lesions in human popula-
tions[12,13]. The mTOR pathway is also important in
oncogenesis as PTEN, a tumor suppressor that functions
upstream of mTOR, is mutated in many brain, prostate
and other tumors[14]. Therefore, there is significant effort
toward evaluating mTOR inhibitors as anti-cancer agents.
There are currently four mTOR inhibitors (Sirolimus, CCI-
779, RAD001, AP23575) being evaluated in a variety of
malignancies including cancers of the brain, kidney,
breast, ovaries, and lung as well as in leukemia and lym-
phoma [15]. CCI-779 (Torisel™ or temsirolimus, Wyeth)
is now FDA-approved for the treatment of advanced renal
cancer, and there is also some evidence for response to
CCI-779 in glioblastomas, metastatic breast cancer, man-
tel cell non-Hodgkin's lymphoma, and Kaposi's sarcoma
[16-20].
The cytokine interferon-gamma (IFN-γ) is another poten-
tial therapeutic agent for the treatment of TSC. It has been
shown that the presence of a high-expressing IFN-γ allele
significantly reduces the burden of kidney tumors in
Tsc2+/- mice relative to that of Tsc2+/- mice with normal
IFN-γ levels[21]. We have also observed an association
between the presence of a high-expressing IFN-γ allele and
reduced frequency of kidney angiomyolipomas in a
cohort of human TSC patients [22].
Recently, we demonstrated that exogenous IFN-γ is an
effective single agent in the treatment of TSC-related
lesions in mouse models [10] and the combination of
CCI-779 plus IFN-γ was more effective than single agents
in a nude mouse model [11]. In our prior study, we
showed that increased cell death along with decreased cell
proliferation are important mechanisms underlying the
antitumor activity of combination treatment in a nude
mouse model for TSC-related tumors. Here, we have used
Tsc2+/- mice to investigate the effects of treatment with
CCI-779 or a combination of CCI-779 plus IFN-γ at differ-
ent time periods. We have also directly compared the effi-
cacy of rapamycin with that of CCI-779 in a Tsc2-/- tumor-
bearing mouse model.
Results
Timing of Treatment and Combination Therapy in Tsc2+/- 
Mice
Tsc2+/- mice were used for a seven-arm preclinical study to
determine the impact of the timing of treatment for TSC
renal disease and to compare treatment with CCI-779 to
CCI-779 plus IFN-γ. The arms of the study are as listed in
Table 1. All mice receiving drug treatment were treated for
a two-month time period (2–4 months, 6–8 months, or
10–12 months). Because the primary goals were to evalu-
ate timing of treatment with an mTOR inhibitor, and
comparison of treatment with an mTOR inhibitor to the
combination of an mTOR inhibitor plus IFN-γ, a group
treated with single agent IFN-γ was not included in this
experiment. The severity of kidney disease was evaluated
using quantitative histopathology to obtain total lesion
counts (Fig. 1a, c) and total kidney scores (Fig. 1b, d) as
described in Methods. Because the development of kidney
cystadenomas in Tsc2+/- mice is age-dependent, disease
severity was evaluated at age 52 weeks in all mice. To illus-
trate the timing of the genesis of kidney tumors in this
mouse strain, the same methods were used to quantitate
severity of kidney disease in six untreated mice (three
males, three females) at each of three additional time
points (3, 7 and 11 months, see Fig. 1e, f).
Compared with untreated controls, a significantly low-
ered burden of disease was observed, as evaluated both by
tumor number and by tumor score, in all mice treated
from 6–8 or 10–12 months of age, regardless of treatment
(Fig. 1c, d). Treatment with CCI-779 or the combination
of CCI-779 plus IFN-γ from 2–4 months was not effective.
There was no significant difference between the 6–8BMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
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month cohort versus the 10–12 month cohort. Further-
more, no benefit was observed from adding IFN-γ to CCI-
779 at any treatment time point. The lack of improvement
with the combination therapy in this study using Tsc2+/-
mice differs from the results we have previously reported
in nude mice bearing Tsc2-/- tumors [11]. As shown (Fig.
1e, f), there are few kidney cystadenomas in untreated
Tsc2+/- mice at 3 months but they are easily observed at 7
months and the severity of kidney disease increases by 11
months.
Treatment with CCI-779 or CCI-779 plus IFN-γ reduced kidney tumor burden in Tsc2+/- mice Figure 1
Treatment with CCI-779 or CCI-779 plus IFN-γ reduced kidney tumor burden in Tsc2+/- mice. The cohorts 
treated with CCI-779 received 8 mg/kg by IP injection Monday through Friday for two months at the indicated ages. The 
cohorts treated with both agents received 8 mg/kg CCI-779 and 20,000 units IFN-γ by IP injection Monday through Friday for 
two months at the indicated ages. Severity of kidney disease was quantified both by counting the total number of cystadenomas 
and by scoring all the cystadenomas found. Average number of cystadenomas per kidney for indicated treatment cohort shown 
in bar graph (a) and table (c) format. Average cystadenoma score per kidney for indicated treatment cohort shown in bar graph 
(b) and table (d) format. Red error bars denote a statistically significant difference (P < 0.05) relative to untreated. "Both" in 
panels a-d refers to a combination of CCI-779 and IFN-γ. To illustrate the timing of kidney lesion genesis in untreated Tsc2+/- 
mice, graphs of average number of cystadenomas per kidney (e) and average cystadenoma score per kidney (f) are shown for 
cohorts of mice at different ages (3, 7 and 11 months; n = 6 mice for each age cohort). The asterisks in panels e and f indicate 
that the severity of kidney disease in untreated cohorts at 3 months and 11 months differs significantly from disease severity at 
7 months (t-test, P ≤ 0.05).
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Group n (mice)
Ave. Number of 
Lesions per Kidney P value
 (Ave. ± Std. Err.)  (vs. untreated)
Untreated 12 4.93 ± 0.89 N/A 
2-4 m. CCI-779 12 3.27 ± 0.50 0.1
2-4 m. both 12 5.30 ± 0.74 0.8
6-8 m. CCI-779 12 2.41 ± 0.26 0.009
6-8 m. both 12 2.15 ± 0.54 0.008
10-12 m. CCI-779 12 1.82 ± 0.44 0.003
10-12 m. both 12 1.70 ± 0.71 0.002
Group n (mice) Ave. Score per Kidney P value
(Ave. ± Std. Err.) (vs. untreated)
Untreated 12 9.95 ± 1.59 N/A 
2-4 m. CCI-779 12 6.52 ± 0.94 0.07
2-4 m. both 12 10.21 ± 1.36 0.9
6-8 m. CCI-779 12 6.00 ± 1.01 0.04
6-8 m. both 12 4.04 ± 0.83 0.002
10-12 m. CCI-779 12 3.54 ± 0.76 0.0007
10-12 m. both 12 2.92 ± 0.71 0.0002
f)
d)
e)
c)
b) a)BMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
Page 4 of 15
(page number not for citation purposes)
Subgroup analysis by kidney lesion type (cystic, papillary 
and solid) in treated and untreated Tsc2+/- cohorts)
Although we refer to all Tsc2+/- mouse kidney lesions col-
lectively as cystadenomas, they can be subdivided into 3
subtypes: cystic lesions, papillary lesions, and solid
tumors (see Fig. 2). To investigate genesis of kidney cysta-
denomas in untreated Tsc2+/- mice as well as the impact of
treatment on cystadenoma subtype, kidney lesions were
scored according to cystadenoma subtype (cystic, papil-
lary, or solid). This subgroup data is shown for all treated
and untreated Tsc2+/- cohorts in Figure 3. Cystic lesions
were observed to be the most common subtype in all
cohorts. The untreated cohorts euthanized at different
ages show that there tends to be an upward trend in all
subtypes of kidney lesions between the ages of 3 to 12
months. Although treatment from 2–4 months was not
significantly different than untreated controls, it is inter-
esting to note that in the 2–4 month single agent CCI-779
cohort, there are fewer kidney lesions of all subtypes than
the 2–4 month CCI-779 plus IFN-γ cohort. In the cohorts
treated from 6–8 months, there are reduced numbers of
cystic and solid lesions, but not of papillary lesions (when
compared with 11 and 12 month untreated). When com-
pared with the 7 month untreated cohort, there are similar
numbers of cysts, papillary and solid lesions. In cohorts
treated from 10–12 months, there are reduced numbers of
cystic, papillary and solid lesions compared with the 11
and 12 month untreated cohorts. This data suggests that
treatment with either CCI-779 alone or in combination
with IFN-γ causes regression of all types of lesions (10–12
month treated vs. 11 and 12 month untreated). It there-
fore seems most likely that in the 6–8 month treated
cohort, there is regression followed by regrowth of all
lesion types.
Timing of Treatment and Rapamycin vs. CCI-779 in a 
Nude Mouse Model of TSC
A nude mouse model of TSC was used to further investi-
gate the impact of the timing of treatment and to compare
rapamycin treatment to CCI-779. As described previ-
ously[10,11], nude mice were given subcutaneous injec-
tions of NTC/T2Null cells (Tsc2-/-  Trp53-/-, hereafter
referred to as Tsc2-/- cells) in the dorsal flank to induce
development of TSC-related tumors. Mice were assigned
to one of the following four treatment cohorts when their
tumors reached the prescribed volume for their cohort:
untreated (assigned when tumor volume was ~50 mm3),
early rapamycin treatment (tumor volume ~50 mm3), late
rapamycin (tumor volume ~250 mm3), and early CCI-
779 (tumor volume ~50 mm3). Tumor volumes were
measured and treatment was given daily Monday through
Friday. All mice were euthanized when tumors exceeded
3000 mm3. To compare the cohorts, day 1 for mice in the
early CCI-779 and early rapamycin treatment cohorts was
taken to be the day the mouse received its first treatment
and day 1 for mice in the untreated and late rapamycin
treatment cohorts was taken to be the day on which that
mouse had a tumor volume of approximately 50 mm3.
Two methods were used to evaluate efficacy of drug treat-
ment in the nude mouse model. Average tumor volumes
were plotted for each cohort at all time points with 4 or
more data points for treated cohorts and 3 or more data
points for the untreated control cohort. The unpaired t
test was used to compare tumor volumes from different
cohorts on the last day on which there were 4 or more
mice with tumor measurements (3 or more for the
untreated control cohort because of the smaller sample
size). Survival analysis was done by determining time to
tumor size of 3000 mm3  because animals with large
tumors require euthanasia according to institutional ani-
mal care guidelines.
As expected, all treatments significantly reduced tumor
growth and improved survival (Fig. 4). At day 29, the aver-
age tumor volumes of the early CCI-779-treated cohort
(812 ± 45 mm3) and the early rapamycin-treated cohort
(351 ± 54 mm3) were lower than that of the untreated
cohort (2209 ± 235 mm3). At day 30, the late rapamycin-
treated cohort (537 ± 113 mm3) also had a lower tumor
volume than the untreated cohort (2254 ± 120 mm3).
Mantel-Cox logrank analysis shows improved survival in
all three treatment cohorts when compared with
untreated controls.
Table 1: Treatment cohorts of the Tsc2+/- mouse experiment.
Treatment Number of Mice Time Period of Treatment Age at Euthanization Average Weight at Necropsy (g) 
(Ave. ± Std. Error)
Untreated 12 (6 M, 6 F) N/A 12 months 34.0 ± 2.5
CCI-779 12 (6 M, 6 F) 2–4 months of age 12 months 33.4 ± 2.4
CCI-779 + IFN-γ 12 (6 M, 6 F) 2–4 months of age 12 months 32.1 ± 1.1
CCI-779 12 (6 M, 6 F) 6–8 months of age 12 months 31.7 ± 1.6
CCI-779 + IFN-γ 12 (6 M, 6 F) 6–8 months of age 12 months 29.2 ± 1.7
CCI-779 12 (6 M, 6 F) 10–12 months of age 12 months 30.5 ± 1.6
CCI-779 + IFN-γ 12 (6 M, 6 F) 10–12 months of age 12 months 28.6 ± 1.2BMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
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To investigate treatment timing using this TSC mouse
model, the early rapamycin cohort was compared to the
late rapamycin cohort (Fig. 5). Although the early
rapamycin cohort was observed to have a significantly
lower tumor volume than the late rapamycin cohort on
day 57 (1916 ± 258 mm3 vs. 2708 ± 81 mm3, respectively;
P = 0.03), there was no improvement in survival. The late
rapamycin-treated cohort grew more sharply than the
early rapamycin-treated cohort until approximately day 8,
when the average tumor volume of the late rapamycin
Examples of the three different subgroups of kidney cystadenomas in Tsc2+/- mice Figure 2
Examples of the three different subgroups of kidney cystadenomas in Tsc2+/- mice. All pictures were taken at a 20× 
magnification. a) Cystic lesions. b) Papillary lesions. c) Solid lesions.BMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
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cohort reached 250 mm3 and the mice in this cohort
began to receive treatment; at this point, the average
tumor volume of the late rapamycin cohort decreased
until approximately day 15 when the average volume sta-
bilized and the tumors entered a stage of progressive
growth (Fig. 5b). From this point on, the growth curves of
the two cohorts remained similar.
CCI-779 is an injectable ester analog of rapamycin. It is
more soluble than rapamycin and is known to be con-
verted to rapamycin after injection[23]. Because we have
used CCI-779 in our prior preclinical studies[10,11] and
we are currently using rapamycin in an ongoing clinical
trial[13], we were interested in comparing CCI-779 to
rapamycin using our nude mouse model of TSC. As
shown in Figure 6, early rapamycin treatment was com-
pared with early CCI-779 treatment. Both drugs were
given at 8 mg/kg five days per week (Monday-Friday).
Although both drugs are effective when compared with
untreated control (see Figure 4), rapamycin was more
effective than CCI-779 in reducing tumor growth and
improving survival. Tumor volume at day 46 was 2653 ±
346 mm3 for the CCI-779 cohort and 1221 ± 125 mm3 for
the rapamycin cohort (P = 0.002, t-test). The median sur-
vival was 47 days for the CCI-779 cohort and 62 days for
the rapamycin cohort (P = 0.0007, Mantel-Cox logrank
analysis).
Kidney cystadenoma scores according to treatment cohort and lesion subtype (cystic, papillary, solid) Figure 3
Kidney cystadenoma scores according to treatment cohort and lesion subtype (cystic, papillary, solid). Cystade-
noma score for each subtype is based on number and size of each lesion as described in methods. a) Average scores are plot-
ted according to treatment cohort in graphical format. b) Average total score per kidney and average score per kidney for each 
lesion subtype by cohort in table format. "Both" refers to a combination of CCI-779 and IFN-γ.
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Rapamycin levels in different tissues after treatment with 
rapamycin or CCI-779
Rapamycin levels were measured in cohorts of mice
treated with either rapamycin or CCI-779 in order to
investigate the tissue distribution of rapamycin and to
compare levels after treatment with rapamycin vs. CCI-
779. All mice in this experiment were given either rapamy-
cin or CCI-779 at a dose of 8 mg/kg via intraperitoneal
(IP) injection daily for four days to achieve steady state
drug levels and to approximate the conditions of the nude
mouse experiment. Rapamycin levels were measured in
blood, brain, and kidney tissue from nude mice without
tumors after either 2–4 hours or 24 hours after drug treat-
ment (see Fig. 7a, b and Table 2a). These time points were
selected based on pharmacokinetics of rapamycin and
CCI-779 in humans and pilot studies of rapamycin blood
levels in mice. In humans, rapamycin levels are known to
peak 1–3 hours after oral dosing of rapamycin [24-26]
and 0.74–2.26 hours after CCI-779 injection [16,27].
With rapamycin treatment in humans, there is an excel-
lent correlation between 24 hour trough drug levels and
area under the time-concentration curve (AUC) [26,28].
In pilot mouse studies of rapamycin level measurements
done at 2–4 hours, 6 hours, 12 hours, 24 hours, and 48
hours after injection with rapamycin or CCI-779, meas-
ured rapamycin blood levels were highest at the 2–4 hour
time point following treatment with either drug (data not
shown).
Rapamycin levels were also measured in four tumors from
each cohort from the nude mouse experiment (all tumor
tissue was obtained 2–4 hours after the final drug treat-
ment). The results are shown in Fig. 7c and Table 2b. At
2–4 hours after drug treatment, the average rapamycin
concentration was similar in blood and kidney tissue, but
lower in brain tissue. At 2–4 hours, rapamycin levels were
~2 times higher in blood and kidneys from the rapamy-
cin-treated animals compared with the CCI-779-treated
animals (P < 0.05). Interestingly, at 2–4 hours, rapamycin
levels were 7–8 times higher in brain tissue from the
Improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors due to treatment with either CCI-779 or  rapamycin Figure 4
Improved survival and decreased tumor growth in nude mice bearing Tsc2-/- tumors due to treatment with 
either CCI-779 or rapamycin. a) Average tumor growth over time for indicated treatment cohorts. b) Survival curve for 
indicated treatment cohorts. Mantel-Cox logrank analysis shows improved survival in all treatment cohorts relative to 
untreated. c) Data shown in table format. P values listed are in comparison to the untreated cohort.
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rapamycin-treated animals compared with the CCI-779-
treated animals (this difference approached statistical sig-
nificance, P = 0.06). At 2–4 hours, blood rapamycin levels
were 1.6–2.2 times higher in blood compared with tumor
tissue after treatment with either rapamycin or CCI-779.
At 24 hours after rapamycin treatment, rapamycin con-
centration was highest in kidney tissue and similar in
blood and brain tissue with brain > blood. At 24 hours
after CCI-779 treatment, rapamycin levels were higher in
kidney tissue than in brain and blood with blood > brain.
At 24 hours, rapamycin levels were 1.3–1.5 times higher
in blood and kidneys from the rapamycin-treated animals
compared with the CCI-779-treated animals. Interest-
ingly, at 24 hours, rapamycin levels were 4–5 times higher
in brain tissue from the rapamycin-treated animals com-
pared with the CCI-779-treated animals (P = 0.003).
These results show that average rapamycin levels in all tis-
sues are higher after rapamycin treatment compared with
CCI-779 treatment at both 2–4 hours and 24 hours.
Because CCI-779 is converted to rapamycin, it is not sur-
prising to see that the tissue levels of rapamycin differ sig-
nificantly at the early time point. It is interesting to see
that comparison of rapamycin treated and CCI-779
treated animals at 24 hours shows that differences in
rapamycin levels are not significant in blood and kidney
tissue. Despite the similarity in blood and kidney levels,
the brain rapamycin concentrations are significantly
higher after rapamycin injection.
Early rapamycin treatment compared to late rapamycin treatment in nude mice bearing Tsc2-/- tumors Figure 5
Early rapamycin treatment compared to late rapamycin treatment in nude mice bearing Tsc2-/- tumors. a) 
Average tumor growth over time for the early rapamycin-treated and late rapamycin-treated cohorts only. b) Enlargement of 
the boxed portion of part a) illustrating the difference in growth pattern between the two treatment cohorts in the first 20 
days of treatment. c) Survival curve for the early rapamycin and late rapamycin-treated cohorts. d) Data shown in table format.
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Discussion
The Tsc2+/- mouse is a useful model for the kidney angi-
omyolipomas that develop in TSC. Both the renal cystad-
enomas that occur in Tsc2+/-  mice and kidney
angiomyolipomas that occur in individuals with TSC tend
not to be present at young ages but develop over time. In
our preclinical study using Tsc2+/- mice, we sought to eval-
uate the importance of timing of a two-month treatment
period with either CCI-779 or CCI-779 plus IFN-γ. Our
results show that if treatment is initiated prior to the
appearance of the kidney lesions (at 2–4 months), the
treatment was not effective. Once kidney lesions are
present, a two-month course of treatment does reduce
kidney disease severity, but there was no difference
between treating at 6–8 months versus 10–12 months.
Our data suggests that there is cystadenoma regression
then regrowth in the cohort treated at 6–8 months, raising
the possibility that there may be benefit to longer term
treatment or continuing a lower maintenance dose to
reduce regrowth of kidney lesions.
There are three studies showing that IFN-γ as a single agent
may be a useful therapeutic agent for TSC kidney disease
[10,21,22]. In a mouse genetic study, the frequency of kid-
ney tumors was dramatically reduced in Tsc2+/- mice engi-
neered to express high levels of endogenous IFN-γ [21]. In
a genetic association study, we demonstrated that a high
expressing allele for IFN-γ is associated with a lower fre-
quency of kidney angiomyolipomas in patients with
known TSC2 mutations [22]. These genetic data in mice
and humans suggest that long term exposure to high lev-
els of IFN-γ may be required for IFN-γ to reduce the sever-
ity of TSC related kidney disease. In our prior preclinical
study using Tsc2+/-  mice [10], single agent IFN-γ was
administered for 10 months (from age 2 months-12
months) and there was significant reduction in the sever-
Early rapamycin treatment is more effective than early CCI-779 treatment in nude mice bearing Tsc2-/- tumors Figure 6
Early rapamycin treatment is more effective than early CCI-779 treatment in nude mice bearing Tsc2-/- 
tumors. All animals were treated with 8 mg/kg of indicated drug five days per week. a) Average tumor growth over time for 
indicated cohorts. b) Survival curve for the early rapamycin and early CCI-779-treated cohorts. c) Data shown in table format.
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ity of kidney disease. We have previously compared the
combination of CCI-779 plus IFN-γ with single agent CCI-
779 and single agent IFN-γ in nude mice bearing Tsc2-/-
tumors and found a significant reduction in tumor growth
and improved survival with combination therapy [11]. In
contrast, here we evaluated combination CCI-779 plus
IFN-γ using Tsc2+/- mice and found no benefit to adding
the IFN-γ to CCI-779 in this study. After considering the
details of these relevant prior studies, we conclude that
this discrepancy is likely due to the shorter IFN-γ treat-
ment duration (2 months) compared with our prior study
(10 months) using Tsc2+/- mice, along with insufficient
power to detect a minor difference between the groups. A
comparison of our prior studies using nude mice bearing
TSC-related tumors also suggests that early treatment with
IFN-γ yields a better response. In Lee et al., 2005 we
treated animals on day 18 after Tsc2-/- cells were injected
and tumors were small (range 0–32 mm3, average of 6.7
mm3) and we observed a dramatic improvement with
IFN-γ treatment. In Lee et al., 2006, the study design dif-
fered as IFN-γ treatment was initiated when subcutaneous
tumors were significantly larger (500 mm3), and although
Blood and tissue rapamycin levels from nude mice treated with rapamycin or CCI-779 Figure 7
Blood and tissue rapamycin levels from nude mice treated with rapamycin or CCI-779. All mice were treated via 
IP injection at a dose of 8 mg/kg of indicated drug once per day and were euthanized either 2–4 hours or 24 hours after the 
final treatment was administered. Whole blood, brain, kidney, and tumor tissue were collected at necropsy. a) Blood, brain, 
and kidney rapamycin levels from cohorts treated with rapamycin or CCI-779 for four consecutive days and euthanized 2–4 
hours after drug injection. b) Blood, brain, and kidney rapamycin levels from cohorts treated with rapamycin or CCI-779 for 
four consecutive days and euthanized 24 hours after drug injection. c) Tumor rapamycin levels from indicated cohorts treated 
with rapamycin or CCI-779 and euthanized 2–4 hours after drug injection. Rapa = rapamycin. This data is shown in table for-
mat with statistical analyses in Table 2.
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single agent IFN-γ was still somewhat effective, the
response was subtle. In the Tsc2+/- study reported here, we
observed that the combination treatment cohort had a
lower cystadenoma score than the single-agent CCI-779
cohort in both the 6–8 month and 10–12 month groups,
although this difference was not statistically significant
(Figure 1a–d). It is possible that early and prolonged IFN-
γ treatment along with larger cohorts might allow us to
observe a difference between combination treatment ver-
sus single-agent CCI-779 treatment in Tsc2+/- mice, and
these issues will be considered in the design of future pre-
clinical studies. It was surprising to see that when we com-
pare the group treated with single agent CCI-779 from 2–
4 months to the group treated with CCI-779 plus IFN-γ
from 2–4 months, single agent CCI-779 looks signifi-
cantly better than combination treatment (P = 0.03). This
finding is puzzling as it is not consistent with other treat-
ment time points in this study or findings in our prior
studies on combination therapy, and we do not have a
good explanation for this difference. Since neither 2–4
month treatment group differed significantly from the
untreated control group, we conclude that the difference
between CCI-779 and combination treatment at this time
is not important.
Loss of heterozygosity has been observed in kidney angi-
omyolipomas[29] and subependymal giant cell
tumors[30]. Because TSC is a tumor suppressor gene syn-
drome, nude mice bearing Tsc2-/- tumors are a useful
generic model for TSC-related tumors. We used this
model to investigate treatment timing and to compare
two mTOR inhibitors. In our comparison of treatment ini-
tiated at tumor size of 50 mm3 vs. tumor size of 250 mm3,
we found that there was a statistically significant reduc-
tion in tumor volume with earlier rapamycin treatment
but no survival advantage. In the later rapamycin treat-
ment cohort, the tumors underwent regression then
regrowth. This is evidence that there is response followed
by development of resistance. We have shown previously
that progressive tumor growth occurs even though the
mTOR pathway is inhibited (as demonstrated by reduced
pS6) [11]. Although dramatic benefit of earlier treatment
was not observed in this experiment, there may be a slight
advantage of earlier treatment as we did observe a reduc-
tion of tumor volume in the early treatment cohort.
Because our prior preclinical studies have used the
rapamycin analog, CCI-779, and rapamycin is being used
in ongoing clinical trials, we sought to demonstrate that
rapamycin and CCI-779 were equally effective using our
nude mouse model for TSC. To our surprise, we found
that although both drugs were effective, rapamycin was
more effective than CCI-779 when given at the identical
dose (in milligrams) as demonstrated by reduced tumor
growth and improved survival. Since CCI-779 is an ester
analog of rapamycin that is known to be a prodrug which
is converted to rapamycin after injection[23], we evalu-
ated rapamycin levels in blood, brain, tumor and kidneys
after injection with either rapamycin or CCI-779. We
found that average rapamycin levels are higher in blood,
kidneys, brain, and tumor tissue 2–4 hours and 24 hours
after rapamycin treatment compared with CCI-779 treat-
ment. At 24 hours, the difference in rapamycin levels from
the two treatment groups was statistically significant only
Table 2: Average rapamycin levels (ng/mL) ± standard errors in blood, brain, kidney, and tumor tissue.
Rapamycin levels at 2–4 hours and 24 hours in blood, kidney, and brain
2–4 Hours Post-Treatment 24 Hours Post-Treatment
Rapamycin 8 mg/kg CCI-779 8 mg/kg P value* Rapamycin 8 mg/kg CCI-779 8 mg/kg P value*
Number of Mice 4 4 4 4
Whole Blood 1650 ± 1715 872 ± 119 0.0003 86 ± 23 68 ± 42 NS
Brain Homogenates 295 ± 227 39 ± 14 NS (0.06) 107 ± 32 24 ± 16 0.003
Kidney Homogenates 1820 ± 264 751 ± 215 0.0003 190 ± 59 126 ± 43 NS
Rapamycin levels at 2–4 hours in tumors from the nude mouse experiment
2–4 Hours Post-Treatment
Early CCI-779 Early Rapamycin Late Rapamycin P value**
Number of Mice 4 4 4
Tumor Homogenates 395 ± 134 965 ± 665 1024 ± 393 NS
*Drug levels from rapamycin cohort compared with CCI-779 cohort for indicated tissue and time point, NS = not significant.
**Tumor drug levels from early CCI-779 cohort and late rapamycin cohort were compared with early rapamycin cohort, NS = not significantBMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
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in brain tissue and not in blood or kidney tissue.
Although a more detailed analysis with additional time
points and larger numbers of animals is required to
understand the pharmacokinetic and phamacodynamic
properties of rapamycin versus CCI-779 in nude mice, our
observation that average rapamycin levels are higher after
rapamycin treatment at both 2–4 hours and 24 hours in
all tissues is consistent with our finding that rapamycin is
more effective than CCI-779, as measured by tumor
growth and survival analysis in nude mice bearing TSC-
related tumors. These results coupled with the fact that
rapamycin has been approved for human use for many
years and consequently has a well-known toxicity profile
make rapamycin our first choice of mTOR inhibitors for
future TSC clinical trials. If neurologic toxicity is observed
with rapamycin in human TSC studies, our results suggest
that CCI-779 may be a useful alternative.
Conclusion
In both the Tsc2+/- mouse model and nude mouse model
for TSC tumors, the timing of initiation of mTOR inhibi-
tor treatment of TSC-related tumors does not appear to be
important, provided that tumors are actively growing at
the time treatment is initiated. Attempting to prevent the
genesis of kidney lesions in Tsc2+/- mice using short term
mTOR inhibitor treatment is not an effective strategy.
Treatment with a combination of IFN-γ and an mTOR
inhibitor for two months did not prove to be more effec-
tive than an mTOR inhibitor alone in Tsc2+/- mice. This
result differs from our findings in the nude mouse tumor
model [11] and could be due to the shorter duration of
IFN-γ therapy used here in Tsc2+/- mice. Finally, rapamycin
proved to be more effective than its analog CCI-779 at
equal doses. Rapamycin treatment results in higher brain,
kidney and tumor levels of rapamycin than treatment
with an equal dose of CCI-779. As TSC is a multi-system
disorder that affects the brain, kidneys and other organs,
depending on TSC disease manifestations and toxicity
profile, it may ultimately be advantageous to have mTOR
inhibitors with differing tissue distribution profiles. We
anticipate these preclinical studies will influence the
design of future preclinical studies and clinical trials for
TSC.
Methods
Tsc2+/- mice and treatment with CCI-779 or CCI-779 plus 
IFN-γ
The Tsc2+/- mice are heterozygous for a deletion of exons
1–2 and have been described previously[31]. The Tsc2+/-
cohort used in these experiments was generated from a
cross with wild-type C57BL/6 mice. Sibling littermates
were used as controls to avoid bias due to strain variation.
Tsc2+/- mice were assigned to one of seven cohorts based
on treatment given and the time period in which treat-
ment was given. All treatments were given by IP injection.
Cohorts included treatment with either CCI-779 alone or
CCI-779 in combination with IFN-γ, and treatment was
given from 2–4 months of age, 6–8 months of age, or 10–
12 months of age (Table 1). All mice in these cohorts were
euthanized at 52 weeks of age according to institutional
animal care guidelines. Mice treated from 10–12 months
of age were euthanized within 2–4 hours after the final
treatment was given. The severity of kidney disease was
determined in all animals using quantitative histopathol-
ogy as described below.
Tsc2+/- mice were treated for 2 months with 8 mg/kg CCI-
779 or a combination of 8 mg/kg CCI-779 and 20,000
units murine IFN-γ administered by IP injection daily
Monday through Friday. This dose and schedule were
selected on the basis of earlier experiments [11]. CCI-779
powder was obtained from Wyeth (Madison, NJ). A 30
mg/mL stock of CCI-779 was made in ethanol (stored at
20°C for up to one week), diluted to 1.2 mg/mL in vehicle
(5% PEG, 5% Tween-80) and administered within 24
hours. Murine IFN-γ (R&D Systems, Minneapolis, MN)
was diluted to 100,000 units/mL in PBS containing 0.1%
mouse serum albumin (Sigma-Aldrich, Inc., St. Louis,
MO), stored at 4°C, and administered within 24 hours.
All animals were checked 5 times per week and their gen-
eral behavior was monitored. Animals were weighed
weekly, and at the time of necropsy, there were no signif-
icant differences in weight between cohorts (average
weights at necropsy shown in Table 1). All experiments
were done according to animal protocols approved by our
institutional animal protocol review committee (Chil-
dren's Hospital Boston, Boston, MA) and were compliant
with federal, local, and institutional guidelines on the care
of experimental animals.
Quantitation of kidney cystadenomas in Tsc2+/- mice by 
histopathology
For quantitative histopathologic examination, each kid-
ney was fixed and sliced at 1 mm intervals. The slices were
then arranged sequentially for paraffin embedding, sec-
tioning, and staining with hematoxylin and eosin (H&E).
Slides were coded and all cystadenomas were counted,
measured, and scored according to the scale shown in
Table 3 by a blinded observer (AR). For cystadenomas that
extended into more than one 1 mm kidney slice, only the
largest cross-sectional area was scored and used for the
analyses. Lesions smaller than 0.01 mm2 in cross-sec-
tional area were not counted towards the analyses. To
illustrate the timing of kidney tumor genesis in untreated
Tsc2+/- mice from this colony, kidneys were also collected
from untreated mice at 3, 7 and 11 months.
Because the kidney cystadenomas that occur in Tsc2+/-
mice can be divided into subgroups that include cystic,
papillary and solid lesions, we use the term "kidney cysta-BMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
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denomas" to refer to the entire spectrum of kidney lesions
observed. In addition to analyzing data according to all
cystadenomas, a subgroup analysis was also done by cod-
ing cystic, papillary, and solid kidney lesions separately.
For the subgroup analysis, lesions with areas that were
≤25% filled with abnormal cells were labeled as cystic,
lesions with areas that were >25% filled in with abnormal
cells were labeled as papillary, and those that were com-
pletely filled with abnormal cells were labeled as solid.
Examples of each of these types of lesions can be found in
Figure 2. Subgroup data is presented as kidney lesion
score per kidney where the subgroup score is based on the
number and size of each type of lesion as described above.
Induction of subcutaneous Tsc2-/- tumors in nude mice and 
treatment with CCI-779 or rapamycin
Nude mice (strain CD-1nuBR, 7 weeks old) were obtained
from Charles River Laboratories (Wilmington, Massachu-
setts). 24 nude mice were injected subcutaneously on the
dorsal flank with 2.5 million NTC/T2null (Tsc2-/-, Trp53-/-
) cells, as in previous studies[10,11]. Tumors were meas-
ured with calipers daily Monday through Friday. Tumor
volumes were calculated by use of the formula L × W × W
× 0.5[32]. Mice were randomly assigned to four cohorts of
six mice each at the time small tumors were visible with
volumes ~5–10 mm3. Cohorts included untreated, early
CCI-779-treated, early rapamycin-treated, and late
rapamycin-treated. Mice in the early CCI-779- and early
rapamycin-treated cohorts began treatment when tumors
reached a volume of approximately 50 mm3 and mice in
the late rapamycin treated cohort began treatment when
tumors reached a volume of approximately 250 mm3. All
treatments were given daily Monday through Friday via IP
injection. Mice were euthanized when tumor volumes
exceeded 3000 mm3, and within 2–4 hours after the final
treatment. All tumor-bearing animals were euthanized
according to institutional animal care guidelines based on
tumor size or presence of an open ulcer. Tumor tissue was
harvested for rapamycin level testing as described below.
We excluded three mice from our analysis of this experi-
ment. One mouse assigned to the early CCI-779 cohort
was euthanized with a small tumor (<50 mm3) prior to
CCI-779 treatment because of weight loss and dehydra-
tion that appeared to be unrelated to drug treatment or
tumor burden. Two mice assigned to the untreated cohort
were housed with mice undergoing treatment with high
doses of topical CCI-779 or rapamycin ointment as part of
a separate pilot experiment. These animals were excluded
from the data analysis because it was determined that this
environmental exposure to rapamycin or CCI-779
affected tumor growth.
Treatment with CCI-779 for the nude mouse experiment
was prepared and administered as described above.
Rapamycin powder was obtained from LC Laboratories
(Woburn, MA) and a 20 mg/mL stock was made in etha-
nol (stored at 20°C for up to one week), diluted to 1.2
mg/mL in vehicle (5% PEG, 5% Tween-80) and adminis-
tered within 24 hours. All animals were checked 5 times
per week and their general behavior was monitored. Ani-
mals were weighed weekly, and at the time of necropsy,
there were no significant differences in weight between
cohorts (data not shown). We did not observe significant
toxicity from treatment with rapamycin or CCI-779 at the
doses used in this study.
The study design of this experiment differs from our prior
study designs [10,11]. In [10], all treatment started on the
same day regardless of tumor size and in [11], treatments
were started when tumor volumes were 500 mm3. Meth-
ods for determining rapamycin levels in tumors from this
experiment are described below.
Rapamycin levels in tumors and other tissues
Rapamycin levels were measured from Tsc2-/- tumor sam-
ples from all treatment cohorts in the nude mouse exper-
iment described above. Tumors were harvested 2–4 hours
after the final treatment and then 200 mg of tumor tissue
was homogenized in 1 mL of sterile saline. Rapamycin
levels were measured by the Clinical Laboratory at Chil-
dren's Hospital Boston (Boston, MA). To further investi-
gate the tissue distribution of rapamycin after treatment
with either rapamycin or CCI-779, rapamycin levels were
also measured in blood, kidneys and brains from nude
mice with no tumors. For these measurements, sixteen
nude mice of the same strain and age used in the nude
mouse tumor experiment described above were treated
with an 8 mg/kg dose of either rapamycin or CCI-779
daily for four days. Blood and tissues were obtained either
2–4 hours or 24 hours after the final dose (see Table 2).
Whole blood was drawn into a syringe via cardiac punc-
ture, dispensed into an EDTA-containing blood tube, and
diluted with an equal volume of sterile saline to ensure
sufficient volume for rapamycin level analysis. Brains and
kidneys were snap-frozen in liquid nitrogen upon collec-
tion and were later thawed and homogenized in sterile
saline at a concentration of 200 mg of tissue per mL of
Table 3: Scoring scale for kidney cystadenomas.
Score Area Range (mm2)
10 . 0 1  <  x  ≤ 0.09
20 . 0 9  <  x  ≤ 0.2
30 . 2  <  x  ≤ 0.35
40 . 3 5  <  x  ≤ 0.5
5x  >  0 . 5
Areas of cystadenomas were calculated by multiplying the longest 
axis and its perpendicular axis.BMC Pharmacology 2007, 7:14 http://www.biomedcentral.com/1471-2210/7/14
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saline. Rapamycin levels were measured by the Clinical
Laboratory at Children's Hospital Boston (Boston, MA).
All measured rapamycin levels were then corrected
according to sample dilution.
Statistical Analyses
GraphPad Prism software (version 4.01) was used for all
statistical analyses, and P ≤ 0.05 was considered to indi-
cate significance. All results were replicated independently
from raw data by two observers (AR and MM). The t test
was used for quantitative analyses and Mantel-Cox
logrank analysis was used for survival data where the time
of death is the time of euthanasia due to tumor size of
3000 mm3 or larger.
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